AN2 Therapeutics, Inc. - ANTX
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| Mar 16, 2026 | SCHEDULE 13G | Commodore Capital LP | 9.9% | 3,697,435 | View |
| Mar 16, 2026 | SCHEDULE 13G | Commodore Capital Master LP | 9.9% | 3,697,435 | View |
| Mar 16, 2026 | SCHEDULE 13G | Robert Egen Atkinson | 9.9% | 3,697,435 | View |
| Mar 16, 2026 | SCHEDULE 13G | Michael Kramarz | 9.9% | 3,697,435 | View |
| Mar 13, 2026 | SCHEDULE 13G | Integrated Core Strategies (US) LLC | 6.0% | 2,135,044 | View |
| Mar 13, 2026 | SCHEDULE 13G | Millennium Management LLC | 6.3% | 2,237,102 | View |
| Mar 13, 2026 | SCHEDULE 13G | Millennium Group Management LLC | 6.3% | 2,237,102 | View |
| Mar 13, 2026 | SCHEDULE 13G | Israel A. Englander | 6.3% | 2,237,102 | View |
| Mar 13, 2026 | SCHEDULE 13G | Vivo Opportunity Fund Holdings, L.P. | 8.0% | 2,864,346 | View |
| Mar 13, 2026 | SCHEDULE 13G | Vivo Opportunity, LLC | 8.0% | 2,864,346 | View |
| Mar 13, 2026 | SCHEDULE 13G | Vivo Opportunity Cayman Fund, L.P. | 0.8% | 289,294 | View |
| Mar 13, 2026 | SCHEDULE 13G | Vivo Opportunity Cayman, LLC | 0.8% | 289,294 | View |
| Feb 17, 2026 | SCHEDULE 13G | Almitas Capital LLC | 5.4% | 2,975,164 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Eric Easom | 7.9% | 2,232,004 | View |
| Nov 14, 2025 | SCHEDULE 13G | Almitas Capital LLC | 5.2% | 1,428,323 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.